American Association for Cancer Research

AACR CANCER POLICY MONITOR

CPM

                                                                                                           MARCH 2009

UPDATED: CANCER RESEARCH WILL BENEFIT FROM FY2009 SPENDING BILL


The NIH, NCI and other health agencies will receive a boost in funding this fiscal year

Cancer research is poised to receive an increase in funding this fiscal year (FY) in addition to the short-term funds provided through the recently enacted economic stimulus bill, the American Recovery and Reinvestment Act of 2009 (ARRA).

The FY2009 appropriations package, which was signed into law on March 11, will provide funding increases to the National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA), as well as the Centers for Disease Control and Prevention (CDC) and the Agency for Health Research and Quality (AHRQ).

Spending decisions were postponed last year after the Democratic-led Congress failed to reach an agreement with the previous administration over funding levels. Instead, Congress approved a continuing resolution, a stopgap measure that froze most government programs at FY2008 levels until March 6 and later extended to March 10.  

The $410 billion omnibus appropriations package (H.R. 1105) combines nine FY 2009 appropriations bills into one single piece of legislation. The House approved the bill by a vote of 245-178, largely along party lines, on February 25. It was approved in the Senate on March 10 by a vote of 62-35.

The appropriation levels below are separate from the funds provided through the recently enacted economic stimulus legislation. That funding, including $10 billion for NIH, will not be built into the baseline for appropriations in FY2009 or FY2010.

  • NIH:
    Total: $30.3 billion
    Increase over FY2008: 3.2% ($937.5 million)
  • NCI:
    Total: $4.97 billion
    Increase over FY2008: 2.8% ($133 million)
  • FDA:
    Total: $2.66 billion
    Increase over FY2008: 20.6% ($398 million)

 

Read More from the March Edition of the AACR Cancer Policy Monitor:

Top